Cantor Fitzgerald Reiterates “Buy” Rating for Radius Health, Inc. (RDUS)

Cantor Fitzgerald restated their buy rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a report released on Friday, November 3rd. Cantor Fitzgerald currently has a $58.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on RDUS. BidaskClub lowered shares of Radius Health from a buy rating to a hold rating in a research note on Tuesday, July 11th. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a buy rating in a research report on Monday, July 17th. Zacks Investment Research raised shares of Radius Health from a sell rating to a hold rating in a report on Tuesday, August 8th. Maxim Group reaffirmed a positive rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Finally, Goldman Sachs Group, Inc. (The) reissued a neutral rating and issued a $45.00 price objective on shares of Radius Health in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Radius Health has an average rating of Hold and an average price target of $51.00.

Shares of Radius Health (RDUS) opened at $26.35 on Friday. Radius Health has a 52 week low of $24.66 and a 52 week high of $55.97. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the previous year, the business posted ($1.07) EPS. research analysts expect that Radius Health will post -5.4 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Reiterates “Buy” Rating for Radius Health, Inc. (RDUS)” was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://weekherald.com/2017/11/15/radius-health-inc-rdus-earns-buy-rating-from-cantor-fitzgerald.html.

In related news, VP Brent Hatzis-Schoch bought 1,778 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average cost of $28.09 per share, with a total value of $49,944.02. Following the completion of the purchase, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the stock in a transaction on Thursday, September 14th. The shares were acquired at an average price of $33.45 per share, for a total transaction of $5,017,500.00. Following the acquisition, the insider now owns 5,448,799 shares of the company’s stock, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 367,678 shares of company stock worth $12,271,498. Insiders own 15.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board purchased a new stake in shares of Radius Health in the second quarter valued at about $1,176,000. Vanguard Group Inc. increased its holdings in Radius Health by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after buying an additional 135,071 shares during the last quarter. State Street Corp increased its holdings in Radius Health by 12.9% during the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after buying an additional 213,399 shares during the last quarter. BlackRock Inc. increased its holdings in Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after buying an additional 262,896 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in Radius Health during the second quarter worth about $25,589,000.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply